ReviewTransplantation2026
Bibliometric review of primary effusion lymphoma research: Current status, hotspots, and future prospects.
Review in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsPrimary effusion lymphoma (PEL) is a rare, highly aggressive malignancy that severely affects patient survival. This study aims to help scholars build a comprehensive framework to identify current challenges, opportunities, and development trends.
methodsA total of 2544 relevant articles were retrieved from the Web of Science, PubMed, and Scopus databases, encompassing the primary research findings and methodologies in this field. The analysis results indicate that while the number of studies has shown growth in certain years, there remains a challenge of concentrated research themes and a lack of clinical application.
resultsThe findings revealed that while the United States dominates PEL research, countries in Asia, particularly China and Japan, are also experiencing growth in this domain. Further keyword co-occurrence analysis indicates that current research hotspots in PEL primarily focus on viral mechanisms, immune evasion, and treatment methods. However, clinical treatment-related keywords such as "chemotherapy agents" and "immunotherapy" appear infrequently in the literature, suggesting a significant disconnect between basic research and clinical application.
conclusionThe study reveals the current situation and trend of the growing PEL research around the world. The findings of this study not only illuminate current trends in PEL research but also emphasize the necessity of continued scholarly inquiry to address the multifaceted challenges faced by patients and healthcare providers alike.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.